Review the clinical evidence behind testosterone therapy for postmenopausal women. Learn why a targeted diagnosis matters for sexual health and clinical safety.
In September 2026, the International Society for Sexual Medicine published an evidence summary stating that testosterone therapy may help some women with sexual dysfunction, particularly postmenopausal women diagnosed with hypoactive sexual desire disorder.
Previous clinical consensus often left women with conflicting advice about low desire, while a growing commercial market framed testosterone as a blanket midlife vitality treatment for fatigue, brain fog and weight gain. Many clinicians prescribed testosterone for general muscle-related complaints or mood shifts without substantial evidence, leaving the specific indication for sexual health blurred by broader anti-aging claims. The standard of care struggled to clearly separate distressing, persistent low desire from normal aging changes or other treatable menopausal symptoms. Medical organizations lacked unified guidance on dosing and safety monitoring, creating an environment where patients frequently received mixed messages from their primary care doctors and specialist clinics.
The updated summary reinforces strict parameters for treatment, supported by a 2019 systematic review and meta-analysis of 36 randomized controlled trials involving 8,480 participants. The findings highlight the following clinical updates and safety protocols:
The 2019 Global Consensus Position Statement established clear boundaries for intervention. It concluded that the only evidence-based indication for testosterone therapy in women is the treatment of postmenopausal women diagnosed with hypoactive sexual desire disorder, often abbreviated as HSDD. This statement was endorsed by several major organizations, including the International Society for the Study of Women’s Sexual Health, the North American Menopause Society and the Endocrine Society.
HSDD is not defined simply by having less desire than in earlier life. It refers to a persistently reduced sexual desire that causes personal distress or negatively affects a woman's wellbeing. Before a clinician considers prescribing testosterone, international consensus guidance requires a formal biopsychosocial assessment. This comprehensive evaluation is critical because low desire rarely has a single biological cause.
A thorough assessment looks at vaginal or vulvar symptoms, the side effects of daily medications, mood disorders and relationship factors. Stress, sleep problems and other underlying health conditions can all suppress sexual interest. The International Society for Sexual Medicine presents testosterone as a potential option with or without menopausal hormone therapy. It is not a substitute for evaluating other treatable contributors, nor does it replace estrogen when vaginal dryness or pain is the primary barrier to comfortable sex.
Distinguishing between normal aging shifts and a diagnosable condition requires careful observation. Low desire can stem from a wide array of factors, including relationship stress, poor sleep patterns or the side effects of daily medications. The International Society for Sexual Medicine highlights that addressing these root causes often takes priority over immediate hormonal intervention. A woman might experience reduced physical arousal because of untreated vaginal dryness, making systemic estrogen more appropriate than testosterone.
The diagnostic criteria for hypoactive sexual desire disorder focus heavily on the element of personal distress. A drop in sexual frequency that does not bother the patient does not meet the clinical threshold for medical treatment. The condition only warrants intervention when the persistent lack of desire negatively impacts emotional wellbeing or relationship satisfaction. This distinction protects women from being medicalized simply for experiencing natural midlife changes in their libido.
The 2019 systematic review and meta-analysis provided much-needed clarity on what patients can realistically expect. Researchers examined 46 reports from 36 randomized controlled trials involving 8,480 participants. By pooling this massive dataset, the medical community gained a clearer picture of the therapy's true efficacy limits. The reported standardized effect sizes of 0.36 for desire and 0.28 for arousal point to modest-to-moderate improvements.
These figures represent average outcomes across thousands of women, meaning individual experiences will vary widely. Some patients might see a noticeable improvement in their sexual responsiveness and self-image, while others may experience no tangible benefit at all. Measuring an increase of 0.85 satisfactory sexual events provides a concrete statistical benchmark, but it does not capture the complex emotional reality of female intimacy. True sexual wellbeing encompasses physical comfort, emotional connection and mental presence, none of which can be guaranteed by a single hormone replacement.
If you want to read more about navigating intimacy changes, we discuss this deeply in our coverage of intimacy and physical comfort.
While the randomized-trial meta-analysis did not identify serious adverse events during the study periods, long-term safety data remains incomplete. The available trials offer stronger evidence for short-term and medium-term sexual-function outcomes than for long-term cardiovascular, breast or endometrial safety. A lack of serious safety signals in these specific trials should not be interpreted as absolute proof that testosterone carries zero risk over many years of use.
Short-term androgenic side effects warrant careful monitoring. Potential changes include acne and increased facial or body hair. Excessive androgen exposure could lead to voice changes or clitoral enlargement, and some of these androgenic changes may be difficult to reverse. This reality explains why clinical guidance strongly stresses maintaining hormone levels within the normal female physiological range.
Clinicians do not use testosterone blood levels alone to diagnose HSDD. A baseline testosterone measurement simply serves as a reference point for later monitoring. Follow-up blood tests help confirm that the dose is not causing supraphysiological levels, which protects the patient while evaluating the actual clinical benefits and any emerging side effects.
You can read more about the intersection of physical and emotional identity in our broader psychological transition reporting.
Even with growing patient interest, women face significant practical hurdles when seeking evidence-based treatment. According to September 2026 coverage by Reuters, the United States currently has no testosterone product approved specifically for women. Consequently, providing this therapy often involves off-label use of products that were originally labeled for men or the creation of compounded formulations.
This lack of a female-specific approval creates ongoing complications regarding dose selection, pharmacy access and insurance coverage. Reuters reported that women frequently encounter prescription delays or outright denials. Patients may also find themselves asked to use gels or creams packaged entirely for male physiology, which complicates the precise dosing required to avoid androgenic side effects.
The regulatory gap also fuels a fragmented market environment. Compounded testosterone preparations and implanted pellets require particular caution. Medical guidance warns about insufficient evidence surrounding these methods and the distinct possibility of supraphysiological dosing. A prescription marketed with terms like optimization or bioidentical does not automatically prove that the treatment is safe or appropriate for a defined medical condition.
For a wider perspective on navigating clinical options during midlife, read our detailed hormonal transition guidance.
For a woman aged roughly 38 to 65, making sense of this data requires a grounded approach to symptom management. The first step involves focusing on the symptom itself rather than chasing a specific number on a lab report. A meaningful medical conversation centers on persistent, distressing low desire, rather than asking if a blood test shows low testosterone. Low desire is not synonymous with low testosterone, and replacing the hormone is not always the correct medical intervention.
Women should actively ask for a broad physical and psychological assessment. A thorough doctor will consider sleep disruption, vaginal discomfort, depression and stress before attributing sexual changes solely to a hormone deficiency. It is also vital to clarify the specific treatment goal. Patients should understand that the evidence supports testosterone for postmenopausal HSDD, not for resolving general fatigue or reversing weight changes. Some clinicians continue prescribing it for fatigue or muscle-related complaints, but the Reuters report notes a distinct lack of equivalent evidence or guideline support for those specific goals.
When treatment is prescribed, the evidence favors physiologic, non-oral delivery methods to protect lipid health. Patients must plan for baseline and follow-up monitoring. If therapy is initiated, a lack of meaningful benefit by the six-month mark should prompt a frank discussion about stopping the treatment. Reassessment prevents indefinite continuation of an ineffective therapy, keeping the focus strictly on measurable improvements in quality of life. Understanding these protocols helps women make informed choices about their bodies, a central theme in our editorial focus on muscle and physical strength.
The current consensus represents the strongest available data, yet the medical community continues analyzing how these treatments impact women over a lifetime. Clinicians rely on emerging studies to better understand the nuanced differences between various compounding methods and standardized pharmaceutical applications. This ongoing observation helps refine the best practices for baseline testing and ongoing symptom evaluation. Women navigating these decisions benefit most when their healthcare providers remain engaged with current, peer-reviewed findings rather than relying on outdated protocols.
By remaining anchored to established facts, patients can separate genuine medical progress from commercial marketing strategies. This clarity empowers women to seek the specific clinical care they require while avoiding unnecessary interventions.
Moving forward, clinical practice will increasingly treat female testosterone therapy as a highly specific intervention for diagnosed sexual dysfunction rather than a generic solution for midlife aging.
While determining the appropriate clinical use of testosterone requires direct medical consultation, finding reliable context for navigating these physical shifts is where Refemina steps in. We address the frustration of health content that treats every problem as a supplement, hormone or weight-loss opportunity, translating credible evidence into clear adult guidance so you can approach midlife with confidence.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources